拉米夫定/多替拉韦用于病毒学抑制且预期或确认对拉米夫定耐药的受试者 (VOLVER)
拉米夫定/多替拉韦在病毒学抑制且预期或确认对拉米夫定耐药的受试者中的病毒学结果。
多替拉韦 (DTG) 加拉米夫定 (3TC) 是一种双重方案组合,推荐用于感染 HIV-1 的未感染者和受抑制者1。 然而,目前关于该方案对有既往耐药史或病毒学失败史的受抑制患者疗效的数据目前不足。 这是一项 IIa 期、开放标签、单臂、多中心研究。
假设是 DTG/3TC 疗法能够在 HIV 感染参与者中维持病毒控制,这些参与者既往有 3TC 耐药史,但在基线前病毒 DNA 群体测序中没有 M184V/I 耐药突变的证据。 研究人员还假设,在转换之前通过下一代 (NGS) 测序检测到的已存档少数 3TC 耐药性相关突变不会对 DTG/3TC 的疗效产生重大影响。
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alicante
-
Alicante、Alicante、西班牙
- H. de Elche
-
Alicante、Alicante、西班牙
- H. General de Alicante
-
-
Barcelona
-
Barcelona、Barcelona、西班牙
- H. Bellvitge
-
Barcelona、Barcelona、西班牙
- H. Clinic
-
Barcelona、Barcelona、西班牙
- H. del Mar
-
-
Coruña
-
A Coruña、Coruña、西班牙
- CHUAC
-
-
Donostia
-
Donostia / San Sebastian、Donostia、西班牙
- H. de Donosti
-
-
Madrid
-
Madrid、Madrid、西班牙
- Hospital 12 de Octubre
-
Madrid、Madrid、西班牙
- H. Fundación Jimenez Díaz
-
Madrid、Madrid、西班牙
- H. Infanta Leonor
-
Madrid、Madrid、西班牙
- H. La Princesa
-
Madrid、Madrid、西班牙
- H. Príncipe de Asturias
-
Madrid、Madrid、西班牙
- H. Severo Ochoa
-
Madrid、Madrid、西班牙
- Hospital General Univ. Gregorio Marañón
-
Madrid、Madrid、西班牙
- Hospital Univ. La Paz
-
-
Málaga
-
Málaga、Málaga、西班牙
- H. Virgen de la Victoria
-
-
Pontevedra
-
Vigo、Pontevedra、西班牙
- H. Álvaro Cunqueiro
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 感染 HIV-1 的成年人(>=18 岁)能够理解并给予知情的书面同意。
筛选访问前 12 周内的稳定 ART。
- 只有在 12 周的窗口内并且只要方案的组成部分不变,才允许出于耐受性/便利性/可及性的原因转用仿制药或从利托那韦转为考比司他或从 TDF 转为 TAF。
筛选时和进入研究前一年的病毒载量 <50 拷贝/mL。
- 如果之前和之后进行了无法检测的 VL 测定,则在纳入研究之前的 48 周内允许出现异常(50-500 拷贝/毫升)。
- 筛选时 CD4 计数 > 200 cel/μL。
3TC 耐药史:确认历史 3TC 耐药(历史 RNA Sanger 或 RNA NGS > 20% 阈值基因型并伴有 M184V/I 突变)或疑似历史 3TC 耐药。
- 怀疑过去的 3TC 抵抗被定义为以下任何一种:
我。先前仅使用 2 种 NRTI 进行治疗(其中 1 种是恩曲他滨或 3TC [XTC])。
二. 在包括 XTC 在内的治疗中连续两次 VL > 200 cp/mL。三. 一个 VL > 200 cp/mL,同时接受治疗,包括由于 VL 升高而改变 ART 的 XTC PLUS。
排除标准:
- 在筛选中具有 M184V/I 或 K65R 的参与者访问前病毒 DNA Sanger 基因型。
- 在基于整合酶抑制剂 (INSTI) 的方案下,既往病毒学失败 (VF)。 定义为在接受 INSTI 时连续两次 VL > 200 拷贝/mL,无论基因型检测结果如何
- 历史 RNA 基因型中的 INSTI 抗性突变。
- 阳性表面乙型肝炎抗原 (HBAgS) 或阴性 HBAgS 和阴性乙型肝炎表面抗体 (anti-HBs) 以及阳性抗核心抗体 (anti-HBc) 和阳性 HBV DNA。
- 孕妇、哺乳期妇女、筛查时妊娠试验呈阳性的妇女、希望怀孕或不愿采取避孕措施的性活跃的育龄妇女(公认的高效避孕方法清单见附录 1),对于研究持续时间和研究药物最后一次给药后 4 周。 所有女性都被认为是可生育的,除非她们在研究开始前接受过绝育手术或年龄超过 50 岁且自发性闭经超过 12 个月。
- 筛查时需要静脉内治疗和/或化疗的活动性机会性感染或癌症患者。
- 根据研究者的说法,任何合并症或使用实验药物的治疗可能会使研究结果产生偏差或给参与者带来额外的风险。
- 接受根据研究药物标签禁用的其他药物的参与者。
- 根据 Child-Pugh 分类确定的严重肝功能损害(C 级)。
- 丙氨酸氨基转移酶 (ALT) 超过正常上限 (ULN) 的 5 倍或 ALT 超过 3xULN 和胆红素超过 1.5xULN。
- 不稳定肝病(定义为存在腹水、脑病、凝血病、低白蛋白血症、食管或胃底静脉曲张或持续性黄疸)、肝硬化、已知的胆道异常(除了因吉尔伯特综合征或无症状胆结石引起的高胆红素血症或黄疸);
- 肌酐清除率 <30 mL/min/1.73m2 通过 CKD-EPI 方法。
- 任何经过验证的 4 级实验室异常,根据研究者的标准,如果纳入研究,将影响参与者的安全。
- 对多替拉韦或拉米夫定过敏的历史或存在。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dovato(多替拉韦+拉米夫定)
治疗:多替拉韦 50 毫克/拉米夫定 300 毫克,一粒薄膜包衣片,每天一次,持续 96 周
|
目前的抗逆转录病毒治疗改为 DTG 50 mg/3TC 300 mg QD
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The Efficacy of a Switch to DTG/3TC for Maintenance of Virologic Suppression, in Persons With Past Confirmed or Suspected 3TC Resistance, When Proviral DNA Population Sequencing Does Not Detect 3TC Resistance-associated Mutations at Baseline.
大体时间:Week 48
|
There were eight participants with no data at week 48: one LTFU, one protocol deviation (M184V at screening), two investigator decision (1 lung cancer, 1 M184V mutation detected in plasma RNA population genotyping at transient rebound, suppressed with dolutegravir/lamivudine not fulfilling criteria for virologic withdrawal), one consent withdrawal and three withdrawals for AEs. It was pre-specified to report all participants who discontinued with last available HIV-1 RNA ≥50 copies/mL in "Number of Participants with HIV-1 RNA ≥50 copies/mL" category at week 48. |
Week 48
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Estimations of Virological Control
大体时间:Week 48 and week 96
|
Proportion of VF (≥50 copies/mL) ITT-e, per protocol population (PP), Proportion of VF (≥200 copies/mL), ITT-e and PP population, FDA snapshot.
Proportion of Confirmed Virologic Withdrawal ([CVW]: A VL≥ 50 copies/mL followed by a VL≥ 200 copies/mL in retest), ITT-e and PP population, FDA snapshot.
Proportion of Precautionary Virologic Withdrawal ([PVW]: three consecutive VL between 50- 200 copies/mL), ITT-e and PP population, FDA snapshot.
Proportion of participants with VL<50 copies/mL, ITT-e and per protocol population, FDA snapshot.
|
Week 48 and week 96
|
|
Viral Resistance in Persons Experiencing VF.
大体时间:Throughout all the study, an average of 96 weeks
|
Percentage of VF with drug resistance associated mutations. - Describe number and type of resistanceassociated mutations in VF |
Throughout all the study, an average of 96 weeks
|
|
Time to VF
大体时间:Throughout all the study, an average of 96 weeks
|
Due to the low number of events, the analysis of factors associated with VF (i.e., time to VF) was not performed.
Additionally, because of the limited number of events, analyses of NGS-related outcomes were conducted only at the 5% level.
The pre-specified subgroup analyses were modified and replaced with analyses based on baseline 3TC or FTC use, confirmed prior resistance to 3TC, and prior exposure to INSTIs.
|
Throughout all the study, an average of 96 weeks
|
|
Proportion of VF in Subgroups: Confirmed Historical M184V/I vs No Resistance Mutations
大体时间:Throughout all the study, an average of 96 weeks
|
Throughout all the study, an average of 96 weeks
|
|
|
Proportion of VF in Subgroups: INSTI Exposure vs No Prior INSTI Exposure
大体时间:Throughout all the study, an average of 96 weeks
|
All participants with M184V/I detected at baseline in proviral DNA NGS had a VL <50 copies/mL at week 48 or last study visit.
|
Throughout all the study, an average of 96 weeks
|
|
Time Virologically Suppressed
大体时间:Throughout all the study, an average of 96 weeks
|
Participants were virologically suppressed for 9 years before the study
|
Throughout all the study, an average of 96 weeks
|
|
Proportion of VF in Subgroup: Time on 3TC/FTC
大体时间:Throughout all the study, an average of 96 weeks
|
Throughout all the study, an average of 96 weeks
|
|
|
Percentage of Participants With VF With Baseline 3TC or INSTI Resistanceassociated Mutations Detected at Baseline by NGS With 1, 5, and 20% Threshold.
大体时间:Throughout all the study, an average of 96 weeks
|
Percentage of VF with drug resistance associated mutations and proportion of participants with VF with baseline 3TC or INSTI resistance- associated mutations detected at baseline by NGS with 5% threshold.
|
Throughout all the study, an average of 96 weeks
|
|
Proportion of Participants With Transient Viral Rebounds With Baseline 3TC or INSTI Resistance- Associated Mutations Detected at Baseline by NGS With 1, 5, and 20% Threshold.
大体时间:Throughout all the study, an average of 96 weeks
|
Proportion of participants with transient viral rebounds with baseline 3TC or INSTI resistance- associated mutations detected at baseline by NGS with 5% threshold.
|
Throughout all the study, an average of 96 weeks
|
|
Number of Participants With M184V/I Presence by Successful Plasma RNA NGS in Participants With Virological Dropout
大体时间:Throughout all the study, an average of 96 weeks
|
Next-generation sequencing (NGS) of plasma RNA was successful in one of the two virological withdrawal cases.
|
Throughout all the study, an average of 96 weeks
|
|
Frequency of Resistance Mutations (RT and Integrase) in Proviral DNA Measured by NGS.
大体时间:Throughout all the study, an average of 96 weeks
|
Throughout all the study, an average of 96 weeks
|
|
|
Change in CD4+ Cell Count
大体时间:Basal, Week 4, Week 12, Week 24, Week 36, Week 48, Week 72 and week 96
|
CD4+ count values were observed throughout the 96 weeks.
|
Basal, Week 4, Week 12, Week 24, Week 36, Week 48, Week 72 and week 96
|
|
Change in CD4+/CD8+ Cell Counts Ratio
大体时间:Basal, Week 4, Week 12, Week 24, Week 36, Week 48, Week 72 and week 96
|
Basal, Week 4, Week 12, Week 24, Week 36, Week 48, Week 72 and week 96
|
|
|
Percentage and Severity of AEs and Laboratory Abnormalities.
大体时间:Basal, Week 48 and week 96
|
Basal, Week 48 and week 96
|
|
|
Proportion of Subjects Who Discontinue Treatment Due to AEs
大体时间:Basal, week 48 and week 96
|
Participants who discontinue treatment due to AEs (al week 96)
|
Basal, week 48 and week 96
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.